The CCG is happy to announce a six month trial of a glucose monitoring system for qualifying patients in the Vale of York.
FreeStyle Libre® will be provided to patients that meet the full criteria of the local commissioning statement which includes:
- patients with Type 1 diabetes mellitus (T1DM) and;
- aged four and above and;
- under specialist care and;
- using multiple daily injections of insulin, or insulin pump therapy, and;
- whom the specialist considers the use of the device will be cost-effective. The use of FreeStyle Libre® is expected to be cost neutral if a patient is currently finger prick testing eight or more times daily. It will be regarded as cost effective when the introduction of FreeStyle Libre® reduces the testing frequency by at least seven times daily.
Details of the trial, jointly produced by colleagues from NHS Scarborough and Ryedale CCG and York Teaching Hospitals NHS Foundation Trust, is based on the Regional Medicines Optimisation Committee suggestion, and adapted to help ensure that local NHS resources are focused on those who will most benefit from this device.
The device, its use and associated costs will be monitored in collaboration with providers, patients and their families over the coming months through a robust audit process.
The trial is expected to run for six months.
About glucose monitoring systems
Glucose monitoring systems are placed into the body but not into the bloodstream and therefore provide continuous glucose monitoring, not blood glucose monitoring.
Blood glucose meters test blood. Glucose monitoring system sensors measure the glucose in interstitial fluid, not blood.
Continuous glucose monitoring systems can be used by insulin pump wearers and those who inject insulin.